Results 81 to 90 of about 5,710 (181)

Retargeting the management of hypercholesterolemia – focus on evolocumab

, 2016
Alessandro Colletti,1 Giuseppe Derosa,2 Arrigo FG Cicero1 1Department of Medical and Surgical Sciences, University of Bologna, Bologna, 2Department of Internal Medicine and Therapeutics, University of Pavia and Policlinico San Matteo Foundation, Pavia ...
Cicero, Arrigo Fg, CICERO, ARRIGO FRANCESCO GIUSEPPE, Derosa, G, Colletti A, Colletti, A, Colletti, Alessandro, DEROSA, GIUSEPPE, Derosa G, Cicero AFG   +8 more
core   +1 more source

Effects of evolocumab therapy and low LDL‐C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes

Endocrinology, Diabetes & Metabolism, 2020
Aims We assessed the change from baseline in vitamin E, steroid hormones, adrenocorticotropic hormone (ACTH), and gonadotropins, overall and by lowest achieved low‐density lipoprotein‐cholesterol (LDL‐C) level, in patients with type 2 diabetes and ...
Dirk J. Blom, Jiyan Chen, Zuyi Yuan, Joao L. C. Borges, Maria L. Monsalvo, Nan Wang, Andrew W. Hamer, Junbo Ge   +7 more
doaj   +1 more source

Evolocumab for early reduction of LDL-C levels in patients with acute ischemic stroke: a randomized controlled trial

Frontiers in Neurology
BackgroundLow-density lipoprotein cholesterol (LDL-C) has been determined as an established risk factor for acute ischemic stroke (AIS). Despite the recommendation for in-hospital initiation of high-intensity statin therapy in AIS patients, achieving the
Xiaohui Qiu, Yeyuan Liang, Yunfei Wei, Mengru Lu, Yujia Mei, Shiting Tang, Jian Tang, Jinyu Liang, Junli Liang   +8 more
doaj   +1 more source

Evolocumab-based LDL-C management in high and very high cardiovascular risk patients in German clinical practice : the HEYMANS study [PDF]

Introduction: Low-density lipoprotein cholesterol (LDL-C) is among the most important modifiable risk factors for cardiovascular disease. In very high-risk patients, the European Society of Cardiology/European Atherosclerosis Society guidelines ...
Fraass, Uwe, Tabbert-Zitzler, Anja, Dhalwani, Nafeesa N., Schettler, Volker, Lehrke, Michael, Vogt, Anja, Girndt, Matthias, Bridges, Ian, Ray, Kausik K.   +8 more
core   +2 more sources

PCSK9 inhibitor in acute ischemic stroke patient receiving mechanical thrombectomy: early outcomes and safety

Frontiers in Neurology
BackgroundLipid-lowering therapies are mainstays in reducing recurrence after acute ischemic stroke (AIS). Evolocumab, a Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, is a promising lipid-lowering agent known to decrease LDL ...
Jonguk Kim, Uichan Hong, Cindy W. Yoon, Jin Woo Bae, Joung-Ho Rha, Hee-Kwon Park   +5 more
doaj   +1 more source

Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON‐CABG CardioLink‐5 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4376-4381, May 2026.
Hwee Teoh, Subodh Verma, G. B. John Mancini, Adrian Quan, Michael Szarek, Randi Elituv, Meena Verma, Elizabeth Misner, Aishwarya Krishnaraj, Peter Jüni, Michael J. Koren, Stephen J. Nicholls, Deepak L. Bhatt, C. David Mazer, Lawrence A. Leiter   +14 more
wiley   +1 more source

Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis

Reviews in Cardiovascular Medicine
Background: Direct comparisons between the drugs are limited, and the dosing remains debatable. Therefore, the study aims to indirectly compare the efficacy and safety of inclisiran, alirocumab, evolocumab, and evinacumab in lipid ...
Lin Zhang, Bin Li, Wei Chen, Wei Li, Huayun Yang, Diguang Pan   +5 more
doaj   +1 more source

Asia–Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study

Cardiology and Therapy
Introduction Real-world data are needed to understand the effectiveness of new therapeutic options for low-density lipoprotein cholesterol (LDL-C) reduction in Asia–Pacific clinical practice.
Hung-Fat Tse, Hung-Yu Chang, David Colquhoun, Jung-Sun Kim, Kian Keong Poh, Karam Kostner, Pisit Hutayanon, Meejin Cho, Jeff Lange, Kamlanathan Kodiappan, Saikiran Leekha   +10 more
doaj   +1 more source

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events [PDF]

, 2015
BACKGROUND: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in short-term studies.
Giugliano, Robert P, Legg, Jason, Blom, Dirk J, Sabatine, Marc S, Scott, Robert, Ballantyne, Christie M, Raal, Frederick J, Robinson, Jennifer, Koren, Michael J, Somaratne, Ransi, Stein, Evan A, Wiviott, Stephen D, Wasserman, Scott M   +12 more
core  

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source